Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update

Key Points

• Lyell Immunopharma experienced a significant **29.3% decrease** in short interest, dropping from 188,200 shares to 133,000 shares as of August 15th.
• The company's stock has an **average rating of "Reduce"** with a target price of **$15.00**, as per analysts' evaluations.
• Lyell Immunopharma reported a quarterly loss of **($2.89) EPS**, which was better than the analysts' forecast of **($3.80) EPS**.

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the recipient of a large decrease in short interest in the month of August. As of August 15th, there was short interest totaling 133,000 shares, adecreaseof29.3% from the July 31st total of 188,200 shares. Based on an average daily volume of 138,400 shares, the short-interest ratio is currently 1.0 days. Approximately2.4% of the shares of the company are short sold. Approximately2.4% of the shares of the company are short sold. Based on an average daily volume of 138,400 shares, the short-interest ratio is currently 1.0 days.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on LYEL. HC Wainwright reissued a "neutral" rating and issued a $10.00 price target on shares of Lyell Immunopharma in a report on Tuesday, June 24th. Wall Street Zen raised shares of Lyell Immunopharma from a "sell" rating to a "hold" rating in a report on Monday, September 1st. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Reduce" and an average price target of $15.00.

Institutional Investors Weigh In On Lyell Immunopharma

Institutional investors have recently modified their holdings of the business. Marshall Wace LLP acquired a new stake in shares of Lyell Immunopharma during the 2nd quarter worth approximately $94,000. Bridgeway Capital Management LLC bought a new position in Lyell Immunopharma during the 2nd quarter worth approximately $159,000. Walleye Capital LLC bought a new position in Lyell Immunopharma during the 2nd quarter worth approximately $258,000. Orbimed Advisors LLC bought a new position in Lyell Immunopharma during the 2nd quarter worth approximately $457,000. Finally, Graham Capital Management L.P. bought a new position in Lyell Immunopharma during the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 66.05% of the company's stock.

Lyell Immunopharma Stock Performance

NASDAQ:LYEL opened at $12.15 on Monday. The company has a 50-day moving average of $10.67 and a 200-day moving average of $10.32. The company has a market capitalization of $233.40 million, a price-to-earnings ratio of -0.50 and a beta of -0.19. Lyell Immunopharma has a 52 week low of $7.65 and a 52 week high of $32.00.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($2.89) EPS for the quarter, topping analysts' consensus estimates of ($3.80) by $0.91. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative net margin of 552,328.31% and a negative return on equity of 85.58%. Sell-side analysts forecast that Lyell Immunopharma will post -0.78 EPS for the current year.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.